Ard Podcast
TULIP 2: Efficacy and Safety of Anifrolumab in Patients
- Author: Vários
- Narrator: Vários
- Publisher: Podcast
- Duration: 0:03:52
- More information
Informações:
Synopsis
TULIP 2: Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus: Results of the Second Phase 3 Randomized Controlled Trial. In this second phase 3 trial, the primary endpoint, BICLA, was achieved, and anifrolumab was superior to placebo for multiple secondary efficacy endpoints, including SRI(4), skin disease, and oral corticosteroid tapering.